4-(4-methylpyrimidin-2-yl)pyridine | 182416-44-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(4-methylpyrimidin-2-yl)pyridine
• 英文别名: 4-methyl-2-pyridin-4-yl-pyrimidine；4-methyl-2-pyridin-4-ylpyrimidine
• CAS: 182416-44-0
• 化学式: C₁₀H₉N₃
• 分子量: 171.202
• InChiKey: ROPRSPWCMFEEBJ-UHFFFAOYSA-N

物化性质

• 沸点：
  231.8±32.0 °C(Predicted)
• 密度：
  1.136±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-methylpyrimidin-2-yl)pyridine 在 sodium tetrahydroborate 、 1-氯乙基氯甲酸酯 作用下， 以 乙醇 、 1,2-二氯乙烷 、 乙腈 为溶剂， 生成 4-(4-methylpyrimidin-2-yl)-1,2,3,6-tetrahydropyridine
  参考文献：
  名称：

  New piperidinyl- and 1,2,3,6-tetrahydropyridinyl-pyrimidine derivatives as selective 5-HT1A receptor agonists with highly potent anti-ischemic effects

  摘要：

  A series of new piperidinyl- and 1,2,3,6-tetrahydropyridinyl-pyrimidine derivatives were synthesized. Among these compounds, 4-methyl-2-(1,2,3,6-tetrahydropyridin-4-yl)pyrimidine derivative 23 (SUN N5147) exhibited sub-nanomolar affinity for 5-HT1A receptor with 1000-fold selectivity over both dopamine D-2 and alpha(1)-adrenergic receptors and remarkable neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.059
• 作为产物：
  描述：

  4-吡啶甲亚胺酸甲酯 在 氯化铵 作用下， 以 1,4-二氧六环 为溶剂， 生成 4-(4-methylpyrimidin-2-yl)pyridine
  参考文献：
  名称：

  New piperidinyl- and 1,2,3,6-tetrahydropyridinyl-pyrimidine derivatives as selective 5-HT1A receptor agonists with highly potent anti-ischemic effects

  摘要：

  A series of new piperidinyl- and 1,2,3,6-tetrahydropyridinyl-pyrimidine derivatives were synthesized. Among these compounds, 4-methyl-2-(1,2,3,6-tetrahydropyridin-4-yl)pyrimidine derivative 23 (SUN N5147) exhibited sub-nanomolar affinity for 5-HT1A receptor with 1000-fold selectivity over both dopamine D-2 and alpha(1)-adrenergic receptors and remarkable neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.059

文献信息

• Pyrimidine derivatives and their salts, useful for making benzoxazepine derivatives
  申请人：Suntory Limited

  公开号：US06337397B1

  公开（公告）日：2002-01-08

  A benzoxazepine derivative having the general formula (I) and its salts and medicaments containing the same as effective ingredients: wherein, n is an integer of 2 to 5, R1 indicates a hydrogen atom, halogen atom, C1 to C4 lower alkyl group, C1 to C4 lower alkoxyalkyl group, C1 to C4 halogenoalkyl group, cyano group, or ester group, R2 indicates a hydrogen atom, halogen atom, C1 to C4 lower alkyl group, C1 to C4 lower alkoxy group, or hydroxy group, a dotted line indicates the presence or absence of a binding bond, W indicates C, CH, or CH2 or a nitrogen atom, provided that, when W is a nitrogen atom, Z is bonded to W and the dotted line indicates the absence of a bond, and Z indicates an unsubstituted or substituted aromatic hydrocarbon ring group or an unsubstituted or substituted heterocyclic group).

  一种具有通式（I）的苯并噁唑啉衍生物及其盐和含有其作为有效成分的药物： 其中，n为2至5的整数，R1表示氢原子、卤原子、C1至C4的低碳基团、C1至C4的低碳氧基碳基团、C1至C4的卤代烷基团、氰基或酯基，R2表示氢原子、卤原子、C1至C4的低碳基团、C1至C4的低碳氧基团或羟基，虚线表示结合键的存在或缺失，W表示C、CH或CH2或氮原子，但当W为氮原子时，Z与W结合，虚线表示缺少结合，Z表示未取代或取代的芳香烃环基团或未取代或取代的杂环基团。
• Benzoxazepine derivatives and their salts and medicaments containing the same
  申请人：Suntory Limited

  公开号：US06187769B1

  公开（公告）日：2001-02-13

  A benzoxazepine derivative having the general formula (I) and its salts and medicaments containing the same as effective ingredients: wherein, n is an integer of 2 to 5, R1 indicates a hydrogen atom, halogen atom, C1 to C4 lower alkyl group, C1 to C4 lower alkoxyalkyl group, C1 to C4 halogenoalkyl group, cyano group, or ester group, R2 indicates a hydrogen atom, halogen atom, C1 to C4 lower alkyl group, C1 to C4 lower alkoxy group, or hydroxy group, a dotted line indicates the presence or absence of a binding bond, W indicates C, CH, or CH2 or a nitrogen atom, provided that, when W is a nitrogen atom, Z is bonded to W and the dotted line indicates the absence of a bond, and Z indicates an unsubstituted or substituted aromatic hydrocarbon ring group or an unsubstituted or substituted heterocyclic group). This benzoxazepine derivative and its salts are useful as medicaments for the treatment of anxiety neurosis, phobias, obsessive-compulsive disorders, schizophrenia, post-cardiac trauma stress, depression, psychosomatic and other psychoneurotic disorders, eating disorders, menopausal disorders, infantile autism and also emesis or disorders involving the cerebral circulatory system accompanying cerebral infarction and cerebral hemorrhage.

  一种具有通式（I）的苯并噁唑啉衍生物及其盐和含有相同有效成分的药物： 其中，n为2至5的整数，R1表示氢原子、卤原子、C1至C4的低碳基团、C1至C4的低碳氧基碳基团、C1至C4的卤代烷基团、氰基或酯基，R2表示氢原子、卤原子、C1至C4的低碳基团、C1至C4的低碳氧基团或羟基，虚线表示结合键的存在或缺失，W表示C、CH或CH2或氮原子，但当W为氮原子时，Z与W结合，虚线表示缺少结合，Z表示未取代或取代的芳香烃环基团或未取代或取代的杂环基团）。 这种苯并噁唑啉衍生物及其盐可用作治疗焦虑神经症、恐惧症、强迫症、精神分裂症、心脏创伤后应激、抑郁症、心身疾病和其他精神神经病性障碍、进食障碍、更年期障碍、婴儿孤独症以及伴有脑梗死和脑出血的脑循环系统紊乱或呕吐症的药物。
• Synthesis and characterization of Sant-75 derivatives as Hedgehog-pathway inhibitors
  作者：Chao Che、Song Li、Bo Yang、Shengchang Xin、Zhixiong Yu、Taofeng Shao、Chuanye Tao、Shuo Lin、Zhen Yang

  DOI：10.3762/bjoc.8.94

  日期：——

  Sant-75 is a newly identified potent inhibitor of the hedgehog pathway. We designed a diversity-oriented synthesis program, and synthesized a series of Sant-75 analogues, which lays the foundation for further investigation of the structure–activity relationship of this important class of hedgehog-pathway inhibitors.

  Sant-75是一种新发现的对刺猬途径具有强大抑制作用的抑制剂。我们设计了一个多样性定向合成计划，并合成了一系列Sant-75类似物，为进一步研究这一重要类别的刺猬途径抑制剂的结构-活性关系奠定了基础。
• ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME
  申请人：Samsung Display Co., Ltd.

  公开号：US20200055886A1

  公开（公告）日：2020-02-20

  Provided are an organometallic compound and an organic light-emitting device including the same.

  提供了一种有机金属化合物和包括该化合物的有机发光器件。
• Organic light-emitting device
  申请人：SAMSUNG DISPLAY CO., LTD.

  公开号：US11056664B2

  公开（公告）日：2021-07-06

  An organic light-emitting device includes a first electrode and a second electrode facing the first electrode. An organic layer is disposed between the first electrode and the second electrode. The organic layer includes an emission layer, a first compound and a second compound.

  一个有机发光器件包括一个第一电极和一个朝向第一电极的第二电极。有机层位于第一电极和第二电极之间。有机层包括一个发射层，一个第一化合物和一个第二化合物。